Johnson & Johnson Expects 2025 Sales Of $91B-$91.8B Versus Prior Guidance Of $90.9B–$91.7B And Consensus Of $90.62B

Benzinga
15 Apr
($ in Billions, except EPS)April 2025January 2025

Adjusted Operational Sales1,2,5

Change vs. Prior Year / Mid-point

2.0% – 3.0% / 2.5%2.0% – 3.0% / 2.5%

Operational Sales2,5 / Mid-point

Change vs. Prior Year / Mid-point

$91.6B – $92.4B / $92.0B

3.3% – 4.3% / 3.8%

$90.9B – $91.7B / $91.3B

2.5% – 3.5% / 3.0%

Estimated Reported Sales3,5/ Mid-point

Change vs. Prior Year / Mid-point

$91.0B – $91.8B / $91.4B

2.6% – 3.6% / 3.1%

$89.2B – $90.0B / $89.6B

0.5% – 1.5% / 1.0%

Adjusted Operational EPS (Diluted)2,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.50 – $10.70 / $10.60

5.2% – 7.2% / 6.2%

$10.75 – $10.95 / $10.85

7.7% – 9.7% / 8.7%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.50 – $10.70 / $10.60

5.2% – 7.2% / 6.2%

$10.50 – $10.70 / $10.60

5.2% – 7.2% / 6.2%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10